

NEWS

Contact:

Robert W. Scherrer
Chief Financial Officer
Genomas, Inc.
TEL: 860-545-4570

FOR IMMEDIATE RELEASE
13 September 2010



Genomas Awarded US Patent for its PhysioGenomics Platform Technology to Predict Treatment Responses

Patent Protects Fundamental Configuration of the Company's PhysioType System Products and Pipeline

HARTFORD, CT – Genomas[®], a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 7,747,392, entitled *Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients* by the US Patent and Trademark Office.

Andreas Windemuth, Ph.D., Chief Technology Officer and co-inventor in the patent stated: “The PhysioGenomics Technology has been successfully applied to several psychiatric and diabetes drugs and to brain imaging. The technology correlates genotypes and phenotypes in patient populations to discover clinically functional variability. The PhysioGenomics Technology integrates a biomedical engineering systems approach with genome probes and nano-arrays.”

Research on the PhysioGenomics Technology has been published in the renowned journals *Annals of Biomedical Engineering*, *Biomedical Engineering Handbook*, *Clinica Chimica Acta*, *Clinics in Laboratory Medicine*, *Molecular Psychiatry*, *Muscle & Nerve*, *Personalized Medicine*, *Pharmacogenomics*, and *Schizophrenia Research*.

Gualberto Rúaño, M.D., Ph.D., President of Genomas and co-inventor commented: “This fundamental patent covers also the configuration of our products and pipeline, the PhysioType[™] Systems. This is a landmark achievement for Genomas and allows us freedom to operate in our industry sector. In an otherwise crowded genomics landscape, and in the presence of an ever more stringent yardstick on novelty versus prior art, this patent significantly increases the value of our intellectual property portfolio and differentiates our proprietary PhysioType products.”

Filed in 2006, US Patent 7,747,392 comprises 23 methods claims and 384 polymorphic DNA sequences representative of 222 key cardiometabolic and neuroendocrine genes. Beyond this patent, the Intellectual Property portfolio of Genomas encompasses 5 patent applications, 2 trademarks, and a copyright on the company's clinical informatics system.

ABOUT GENOMAS

Genomas is a biomedical company advancing DNA-Guided Medicine and personalized healthcare. The company develops revolutionary *PhysioType[™]* Systems for DNA-guided management and prescription of drugs used to treat mental illness and diabetes. PhysioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance. PhysioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk and efficacy among drugs for the individual patient.

The company's clinical pharmacogenetic tests and consultation service are provided through its *Laboratory of Personalized Health* (LPH), an accredited and licensed high-complexity molecular diagnostic center and its *Personalized Health Portal* (PHP), a medical informatics interface for clinician decision support. Genomas is located on the campus of Hartford Hospital. Please visit www.genomas.com for more information.

###